文献速递类风湿关节炎

65岁以上类风湿关节炎患者中低剂量附加泼尼松龙治疗:实用随机双盲安慰剂对照GLORIA试验

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
PubMed 文献 · Ann Rheum Dis · 2022-05-31

GLORIA实用双盲随机试验比较每日5 mg泼尼松龙与安慰剂治疗2年在451例65岁以上活动性类风湿关节炎患者中的获益与危害,结果显示泼尼松龙组疾病活动度DAS28低0.37分、关节损伤进展低1.7分,但发生特殊关注不良事件的患者比例更高(60% vs 49%,校正相对风险1.24),作者认为获益与危害平衡倾向有利。

要点

  • 每日5 mg泼尼松龙治疗2年使DAS28低0.37分、关节损伤进展低1.7分
  • 泼尼松龙组60% vs 安慰剂组49%发生特殊关注不良事件,校正相对风险1.24
  • 两组差异最大的是多为非严重性的感染事件

核心结论

  • 在已确诊类风湿关节炎的老年患者中,附加低剂量泼尼松龙具有有益的长期效果,代价是发生多为非严重不良事件的患者增加24%,提示获益与危害平衡倾向有利。

研究设计与样本

  • GLORIA实用双盲随机对照试验,比较每日5 mg泼尼松龙与安慰剂治疗2年,纳入451例65岁以上活动性类风湿关节炎患者。
  • 允许除长期开放标签糖皮质激素外的所有联合治疗,尽量减少排除标准以适应老年患者。
  • 获益结局包括疾病活动度(DAS28,共同主要结局)和关节损伤(Sharp/van der Heijde评分,次要结局),另一共同主要结局为危害,以发生至少1例特殊关注不良事件的患者比例表示。
  • 特殊关注不良事件包括严重事件、糖皮质激素特异性事件及导致研究终止的事件。
  • 采用纵向模型分析数据,单侧检验,95%置信限。

主要发现

  • 患者已确诊类风湿关节炎,平均2.1种合并症,年龄72岁,病程11年,DAS28 4.5;79%使用改善病情抗风湿药,包括14%使用生物制剂。
  • 泼尼松龙组63% vs 安慰剂组61%完成试验;因不良事件终止两组均为14%,因活动性疾病终止泼尼松龙组3% vs 安慰剂组4%,因其他原因(包括新冠大流行相关疾病)终止泼尼松龙组19% vs 安慰剂组21%;平均在研究中的时间为19个月。
  • 泼尼松龙组疾病活动度DAS28较安慰剂组低0.37分(95% CL 0.23,p<0.0001)。
  • 泼尼松龙组关节损伤进展较安慰剂组低1.7分(95% CL 0.7,p=0.003)。
  • 泼尼松龙组60% vs 安慰剂组49%发生危害结局,校正相对风险1.24(95% CL 1.04,p=0.02),最大差异见于多为非严重性的感染。

关键数值与推荐

  • 每日泼尼松龙5 mg,治疗2年。
  • DAS28较安慰剂组低0.37分(95% CL 0.23,p<0.0001)。
  • 关节损伤进展较安慰剂组低1.7分(95% CL 0.7,p=0.003)。
  • 发生至少1例特殊关注不良事件的患者比例泼尼松龙组60% vs 安慰剂组49%,校正相对风险1.24(95% CL 1.04,p=0.02)。
  • 试验注册号NCT02585258。

临床怎么用

  • 作者认为,在已确诊类风湿关节炎的老年患者中附加低剂量泼尼松龙具有有益的长期效果,代价是发生多为非严重不良事件的患者增加24%,提示获益与危害平衡倾向有利。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. METHODS: The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and those causing study discontinuation. Longitudinal models analysed the data, with one-sided testing and 95% confidence limits (95% CL). RESULTS: We randomised 451 patients with established RA and mean 2.1 comorbidities, age 72, disease duration 11 years and DAS28 4.5. 79% were on disease-modifying treatment, including 14% on biologics. 63% prednisolone versus 61% placebo patients completed the trial. Discontinuations were for AE (both, 14%), active disease (3 vs 4%) and for other (including covid pandemic-related disease) reasons (19 vs 21%); mean time in study was 19 months. Disease activity was 0.37 points lower on prednisolone (95% CL 0.23, p<0.0001); joint damage progression was 1.7 points lower (95% CL 0.7, p=0.003). 60% versus 49% of patients experienced the harm outcome, adjusted relative risk 1.24 (95% CL 1.04, p=0.02), with the largest contrast in (mostly non-severe) infections. Other GC-specific events were rare. CONCLUSION: Add-on low-dose prednisolone has beneficial long-term effects in senior patients with established RA, with a trade-off of 24% increase in patients with mostly non-severe AE; this suggests a favourable balance of benefit and harm. TRIAL REGISTRATION NUMBER: NCT02585258.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022. PMID: 35641125. doi:10.1136/annrheumdis-2021-221957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。